Literature DB >> 25344941

Controversies in Choledochal Malformations: A Survey among Dutch Pediatric Surgeons.

Maria Hendrina Antoinette van den Eijnden1, Ruben H de Kleine2, Henkjan J Verkade3, Jim C H Wilde4, Paul M J G Peeters2, Jan B F Hulscher1.   

Abstract

BACKGROUND: Choledochal malformation (CM) is a rare medical condition of which 80% are diagnosed in pediatric patients. There are several important controversies regarding diagnostic workup, management, and follow-up in these pediatric patients. To assess preferences and practices of Dutch pediatric surgeons regarding the diagnostic procedures, management, and follow-up of children with CM we conducted an electronic survey.
METHODS: A questionnaire was sent to all the pediatric surgeons working in the academic centers and the only community hospital with a pediatric surgery service. The questionnaire included, items regarding incidence, diagnostic workup, interval between diagnosis and surgery, surgical techniques, and follow-up. We also assessed whether personal exposure influenced the preferences and practices.
RESULTS: Overall 22 out of the 31 (71%) Dutch pediatric surgeons returned the questionnaire. Total 15 out of 22 (68%) encountered CM up to 2 times/y, whereas 7 out of 22 (32%) encountered it more than 2 times/y. Indications for surgery were significantly different between surgeons who encountered CM > 2 time/y versus those who did not: 6/6 (100%) of surgeons encountering CM > 2 times/y considered the presence of an asymptomatic CM an indication for surgery versus 5/14 (36%) of the pediatric surgeons who encountered a CM up to 2 times/y (p = 0.01). Overall 12 out of the 22 (55%) respondents preferred surgery between 6 months and 2 years of age. The amount of exposure did not differ in preferred age at surgery or surgical technique. In the symptomatic child 10/22 (45%) of respondents preferred surgery within 3 months. Overall 7/22 (32%) favored laparoscopic resection. Hepaticojejunostomy with Roux-en-Y reconstruction was the preferred reconstruction for all the respondents. One-third stated that they never performed a parenchyma resection. Follow-up was limited to 10 years in almost half of the respondents.
CONCLUSION: Dutch pediatric surgeons demonstrate a wide variety of opinions regarding diagnostic workup, treatment, and follow-up of CM. While most surgeons encounter CM up to 2 times/y, there is an association between exposure and several of the outcome parameters. Some of the answers are not in line with the expert opinion. This demonstrates that there is a need for evidence-based (inter)national guidelines regarding the diagnostic approach, management, and follow-up. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 25344941     DOI: 10.1055/s-0034-1387947

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  3 in total

1.  Choledochal Malformation in Children: Lessons Learned from a Dutch National Study.

Authors:  Maria H A van den Eijnden; Ruben H J de Kleine; Ivo de Blaauw; Paul G J M Peeters; Bart P G Koot; Matthijs W N Oomen; Cornelius E J Sloots; W G van Gemert; David C van der Zee; L W E van Heurn; Henkjan J Verkade; Jim C H Wilde; Jan B F Hulscher
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

2.  Choledochal malformations in adults in the Netherlands: Results from a nationwide retrospective cohort study.

Authors:  Ruben H de Kleine; A Marthe Schreuder; Anneke Ten Hove; Jan B F Hulscher; Inne H M Borel Rinkes; Cornelis H C Dejong; Jeroen de Jonge; Philip de Reuver; Joris Erdmann; Geert Kazemier; Thomas M van Gulik; Annette S H Gouw; Robert J Porte
Journal:  Liver Int       Date:  2020-08-03       Impact factor: 5.828

3.  Survey of the attitudes of hepatopancreatobiliary surgeons in northern Europe to resection of choledochal cysts in asymptomatic Western adults.

Authors:  K W Brudvik; S Yaqub; E Kemsley; M M E Coolsen; C H C Dejong; S J Wigmore; K Lassen
Journal:  BJS Open       Date:  2019-09-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.